1. Home
  2. DSP vs VOR Comparison

DSP vs VOR Comparison

Compare DSP & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Viant Technology Inc.

DSP

Viant Technology Inc.

HOLD

Current Price

$11.81

Market Cap

184.3M

Sector

Technology

ML Signal

HOLD

Logo Vor Biopharma Inc.

VOR

Vor Biopharma Inc.

HOLD

Current Price

$12.50

Market Cap

207.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DSP
VOR
Founded
1999
2015
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
184.3M
207.1M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
DSP
VOR
Price
$11.81
$12.50
Analyst Decision
Strong Buy
Buy
Analyst Count
8
9
Target Price
$18.50
$67.00
AVG Volume (30 Days)
261.6K
3.4M
Earning Date
11-10-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
29.49
N/A
EPS
0.10
N/A
Revenue
$324,131,000.00
N/A
Revenue This Year
$17.79
N/A
Revenue Next Year
$17.72
N/A
P/E Ratio
$120.95
N/A
Revenue Growth
22.97
N/A
52 Week Low
$8.11
$2.62
52 Week High
$26.33
$65.80

Technical Indicators

Market Signals
Indicator
DSP
VOR
Relative Strength Index (RSI) 62.12 49.63
Support Level $11.10 $7.91
Resistance Level $12.26 $16.80
Average True Range (ATR) 0.50 1.70
MACD -0.02 1.00
Stochastic Oscillator 60.75 55.16

Price Performance

Historical Comparison
DSP
VOR

About DSP Viant Technology Inc.

Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. It operates a cloud-based demand side platform ("DSP") that is used by marketers and its advertising agencies to centralize the planning, buying and measurement of its advertising across channels, including connected TV (CTV), streaming audio, digital out-of-home, mobile and desktop.

About VOR Vor Biopharma Inc.

Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.

Share on Social Networks: